TXG Stock Overview
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
10x Genomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.90 |
| 52 Week High | US$63.57 |
| 52 Week Low | US$26.30 |
| Beta | 1.89 |
| 1 Month Change | -25.79% |
| 3 Month Change | -37.76% |
| 1 Year Change | -47.62% |
| 3 Year Change | -86.37% |
| 5 Year Change | n/a |
| Change since IPO | -49.00% |
Recent News & Updates
Recent updates
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 2210x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum
Oct 12Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Oct 0510x Genomics cut to Sell at Goldman Sachs on slower sales ramp
Aug 1810x Genomics: Still Expensive, No Profitability In Sight, And Insiders Are Still Selling
Jul 3010x Genomics guides to Q2 revenues below consensus; shares down 13% after hours
Jul 14Shareholder Returns
| TXG | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -7.1% | 3.6% | 1.0% |
| 1Y | -47.6% | 3.2% | 21.9% |
Return vs Industry: TXG underperformed the US Life Sciences industry which returned 4.7% over the past year.
Return vs Market: TXG underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| TXG volatility | |
|---|---|
| TXG Average Weekly Movement | 6.4% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TXG's share price has been volatile over the past 3 months.
Volatility Over Time: TXG's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 1,259 | Serge Saxonov | www.10xgenomics.com |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell.
10x Genomics, Inc. Fundamentals Summary
| TXG fundamental statistics | |
|---|---|
| Market cap | US$3.21b |
| Earnings (TTM) | -US$255.10m |
| Revenue (TTM) | US$618.73m |
5.2x
P/S Ratio-12.6x
P/E RatioIs TXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TXG income statement (TTM) | |
|---|---|
| Revenue | US$618.73m |
| Cost of Revenue | US$209.41m |
| Gross Profit | US$409.31m |
| Other Expenses | US$664.41m |
| Earnings | -US$255.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -2.14 |
| Gross Margin | 66.15% |
| Net Profit Margin | -41.23% |
| Debt/Equity Ratio | 0% |
How did TXG perform over the long term?
See historical performance and comparison